Bioasis Technologies Inc (CVE:BTI) (OTCQB:BIOAF) executive chair Dr Deborah Rathjen talks Proactive through its research collaboration with Aposense Limited, an Israeli bio-pharmaceutical company specializing in development of novel drugs utilizing membrane electrical forces. The research partnership will focus on the delivery of small interfering RNA (siRNA) into the brain. Dr Rathjen also details new research validating the ability of its xB3 platform to cross the intact blood-brain barrier (BBB) and its localization in a variety of brain cell types.
Bioasis Technologies talks its unique xB3 platform and Aposense collaboration
